Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1310–1315. doi: 10.1038/bjc.1993.243

Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.

J A Calvete 1, D R Newell 1, C J Charlton 1, A F Wright 1
PMCID: PMC1968515  PMID: 8512816

Abstract

A colorectal tumour-directed immunotoxin, ICI D0490, has been constructed by linking recombinant ricin A-chain to C242, a mouse monoclonal antibody, by means of a methyl-hindered disulphide bond. Recombinant ricin A-chain and a hindered disulphide linker were anticipated to confer favourable pharmacokinetic properties on the immunotoxin. The pharmacokinetics of ICI D0490 have been studied in mice following single and repeated i.v. administration. The concentrations of intact immunotoxin in mouse plasma at various time intervals after injection for up to 96 h were measured by a solid-phase enzyme-linked immunosorbent assay (ELISA) and the data analysed by both model-dependent (two compartment) and model-independent methods. Following a single i.v. bolus dose of 2.5 mg kg-1 (50% of the LD10 in mice), the clearance of ICI D0490 from the plasma was extremely slow; 34 microliters min-1 kg-1, t1/2 beta = 33 h. Model-dependent and model-independent analyses gave comparable results with steady state volumes of distribution of 93 and 69 ml kg-1, respectively. The two compartment analysis gave an initial volume of distribution (63 ml kg-1) which is consistent with the predicted plasma volume. Over the dose range 0.05-5 mg ICI D0490 kg-1, plasma levels at 2 and 24 h were linearly related to dose (r > or = 0.98) indicating that at doses up to 5 mg ICI D0490 kg-1 clearance does not appear to have a saturable component. Repeated doses of ICI D0490 (1 mg kg-1 day x 5) did not lead to drug accumulation. These studies demonstrate that ICI D0490 has excellent in vivo stability and persistence which, in conjunction with activity and toxicity data, identify ICI D0490 as a promising candidate for clinical evaluation in the treatment of colorectal cancer.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baeckström D., Hansson G. C., Nilsson O., Johansson C., Gendler S. J., Lindholm L. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J Biol Chem. 1991 Nov 15;266(32):21537–21547. [PubMed] [Google Scholar]
  2. Blakey D. C., Skilleter D. N., Price R. J., Watson G. J., Hart L. I., Newell D. R., Thorpe P. E. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. Cancer Res. 1988 Dec 15;48(24 Pt 1):7072–7078. [PubMed] [Google Scholar]
  3. Blakey D. C., Thorpe P. E. Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. Cancer Drug Deliv. 1986 Summer;3(3):189–196. doi: 10.1089/cdd.1986.3.189. [DOI] [PubMed] [Google Scholar]
  4. Blakey D. C., Watson G. J., Knowles P. P., Thorpe P. E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res. 1987 Feb 15;47(4):947–952. [PubMed] [Google Scholar]
  5. Bourrie B. J., Casellas P., Blythman H. E., Jansen F. K. Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem. 1986 Feb 17;155(1):1–10. doi: 10.1111/j.1432-1033.1986.tb09451.x. [DOI] [PubMed] [Google Scholar]
  6. Byers V. S., Pimm M. V., Pawluczyk I. Z., Lee H. M., Scannon P. J., Baldwin R. W. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents. Cancer Res. 1987 Oct 15;47(20):5277–5283. [PubMed] [Google Scholar]
  7. Byers V. S., Rodvien R., Grant K., Durrant L. G., Hudson K. H., Baldwin R. W., Scannon P. J. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res. 1989 Nov 1;49(21):6153–6160. [PubMed] [Google Scholar]
  8. Endo Y., Mitsui K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem. 1987 Apr 25;262(12):5908–5912. [PubMed] [Google Scholar]
  9. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem. 1987 Jun 15;262(17):8128–8130. [PubMed] [Google Scholar]
  10. FitzGerald D., Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst. 1989 Oct 4;81(19):1455–1463. doi: 10.1093/jnci/81.19.1455. [DOI] [PubMed] [Google Scholar]
  11. Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989 Oct 15;49(20):5656–5663. [PubMed] [Google Scholar]
  12. Gould B. J., Borowitz M. J., Groves E. S., Carter P. W., Anthony D., Weiner L. M., Frankel A. E. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst. 1989 May 10;81(10):775–781. doi: 10.1093/jnci/81.10.775. [DOI] [PubMed] [Google Scholar]
  13. Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., Frankel A. E. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod. 1988 Feb;7(1):97–113. [PubMed] [Google Scholar]
  14. Kuusela P., Haglund C., Roberts P. J. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991 Apr;63(4):636–640. doi: 10.1038/bjc.1991.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Larson L. N., Johansson C., Lindholm L., Holmgren J. Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells. Int J Cancer. 1988 Dec 15;42(6):877–882. doi: 10.1002/ijc.2910420615. [DOI] [PubMed] [Google Scholar]
  16. Newell D. R. Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations. Br J Cancer. 1990 Feb;61(2):189–191. doi: 10.1038/bjc.1990.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pai L. H., Bookman M. A., Ozols R. F., Young R. C., Smith J. W., 2nd, Longo D. L., Gould B., Frankel A., McClay E. F., Howell S. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol. 1991 Dec;9(12):2095–2103. doi: 10.1200/JCO.1991.9.12.2095. [DOI] [PubMed] [Google Scholar]
  18. Spitler L. E., del Rio M., Khentigan A., Wedel N. I., Brophy N. A., Miller L. L., Harkonen W. S., Rosendorf L. L., Lee H. M., Mischak R. P. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 1987 Mar 15;47(6):1717–1723. [PubMed] [Google Scholar]
  19. Sung C., Youle R. J., Dedrick R. L. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res. 1990 Nov 15;50(22):7382–7392. [PubMed] [Google Scholar]
  20. Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988 Nov 15;48(22):6396–6403. [PubMed] [Google Scholar]
  21. Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Knyba R. E., Wawrzynczak E. J., Blakey D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 1987 Nov 15;47(22):5924–5931. [PubMed] [Google Scholar]
  22. Trown P. W., Reardan D. T., Carroll S. F., Stoudemire J. B., Kawahata R. T. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain. Cancer Res. 1991 Aug 15;51(16):4219–4225. [PubMed] [Google Scholar]
  23. Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991 Aug 1;51(15):4052–4058. [PubMed] [Google Scholar]
  24. Wawrzynczak E. J., Cumber A. J., Henry R. V., May J., Newell D. R., Parnell G. D., Worrell N. R., Forrester J. A. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. Cancer Res. 1990 Dec 1;50(23):7519–7526. [PubMed] [Google Scholar]
  25. Wawrzynczak E. J., Cumber A. J., Henry R. V., Parnell G. D. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain. Int J Cancer. 1991 Jan 2;47(1):130–135. doi: 10.1002/ijc.2910470123. [DOI] [PubMed] [Google Scholar]
  26. Wawrzynczak E. J., Henry R. V., Cumber A. J., Parnell G. D., Derbyshire E. J., Ulbrich N. Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus. Eur J Biochem. 1991 Feb 26;196(1):203–209. doi: 10.1111/j.1432-1033.1991.tb15805.x. [DOI] [PubMed] [Google Scholar]
  27. Wawrzynczak E. J. Systemic immunotoxin therapy of cancer: advances and prospects. Br J Cancer. 1991 Oct;64(4):624–630. doi: 10.1038/bjc.1991.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Weiner L. M., O'Dwyer J., Kitson J., Comis R. L., Frankel A. E., Bauer R. J., Konrad M. S., Groves E. S. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989 Jul 15;49(14):4062–4067. [PubMed] [Google Scholar]
  29. Worrell N. R., Cumber A. J., Parnell G. D., Mirza A., Forrester J. A., Ross W. C. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anticancer Drug Des. 1986 Nov;1(3):179–188. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES